APA (7th ed.) Citation

Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, . . . Stephan Weidinger. (2024). Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Adelaide A. Hebert, et al. Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-severe Atopic Dermatitis: 16-week Results from Three Randomized Phase 3 Clinical Trials. Taylor & Francis Group, 2024.

MLA (9th ed.) Citation

Adelaide A. Hebert, et al. Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-severe Atopic Dermatitis: 16-week Results from Three Randomized Phase 3 Clinical Trials. Taylor & Francis Group, 2024.